regulatory

News

Donanemab data an “important advance” in Alzheimer’s

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also

News

FTC asks for more info on Pfizer’s $43bn Seagen takeover

The US Federal Trade Commission (FTC) has asked for more information on Pfizer’s $43 billion agreement to acquire Seagen before it will deliver a decision on whether the d

News

Illumina fined €432m for ignoring Grail merger objection

The European Commission has levied a substantial penalty on DNA sequencing giant Illumina for closing its takeover of cancer detection company Grail without EU regulatory

News

Takeda pulls its dengue vaccine filing from FDA

Takeda has unexpectedly withdrawn its marketing application with the FDA for dengue fever vaccine TAK-003 and said it will reconsider whether it will attempt to bring it t

News

FDA sets out its thinking on psychedelic drug trials

The FDA has published its first-ever guidance document on clinical trials with psychedelic drugs, an emerging treatment category for psychiatric and substance use disorder

News

Intercept changes course as OCA is rejected for NASH again

Intercept Pharma has conceded defeat in its battle to get obeticholic acid (OCA) approved as a treatment for non-alcoholic steatohepatitis (NASH) after the FDA rejected it

Donanemab data an “important advance” in Alzheimer’s

FTC asks for more info on Pfizer’s $43bn Seagen takeover

Illumina fined €432m for ignoring Grail merger objection

Takeda pulls its dengue vaccine filing from FDA

FDA sets out its thinking on psychedelic drug trials

Intercept changes course as OCA is rejected for NASH again

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

regulatory

Editor's Picks